Evidence map›Paper›PMID 31963118›Full record

ArticleViruses2020

Modeling Challenges of Ebola Virus-Host Dynamics during Infection and Treatment.

Daniel S Chertow, Louis Shekhtman, Yoav Lurie, Richard T Davey, Theo Heller, Harel Dahari

Abstract read
In one paragraph

Article in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Mathematical analysis of a within-host model of SARS-CoV-2.Advances in difference equations · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel S ChertowCritical Care Medicine Department, National Institutes of Health Clinical Center, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.ORCID 0000-0002-1675-1728
Louis ShekhtmanThe Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA.
Yoav LurieLiver Unit, Shaare Zedek Medical Center and the Hebrew University of Jerusalem, Jerusalem 9103102, Israel.
Richard T DaveyDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Theo HellerTranslational Hepatology Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Harel DahariThe Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA.ORCID 0000-0002-3357-1817

Funding

Influenza and Emerging Infectious DiseasesZIAAI000984 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DAVEY, RICHARD · 2009 to 2025
$44.1M
Collaborative Integration of HCV Molecular Virology and Mathematical ModelingR01AI078881 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PERELSON, ALAN S, UPRICHARD, SUSAN L. · 2011 to 2025
$7.5M
Collaborative Integration of Hepatitis B Molecular Virology and Mathematical/Computational ModelingR01AI144112 · NIAID · LOYOLA UNIVERSITY CHICAGO · PI DAHARI, HAREL, UPRICHARD, SUSAN L. · 2019 to 2023
$2.2M
Computational discovery of effective hepatitis C intervention strategiesR01GM121600 · NIGMS · LOYOLA UNIVERSITY CHICAGO · PI BOODRAM, BASMATTEE, DAHARI, HAREL · 2017 to 2021
$2.0M
Clinical and Molecular Features of Ebola Virus DiseaseZIACL009024 · CLC · CLINICAL CENTER · PI CHERTOW, DANIEL S · 2017 to 2025
$0k
NIAID NIH HHS R01 AI078881NIAID NIH HHS R01 AI144112NIGMS NIH HHS R01 GM121600
6 · The paper itself

Abstract

Mathematical modeling of Ebola virus (EBOV)-host dynamics during infection and treatment in vivo is in its infancy due to few studies with frequent viral kinetic data, lack of approved antiviral therapies, and limited insight into the timing of EBOV infection of cells and tissues throughout the body. Current in-host mathematical models simplify EBOV infection by assuming a single homogeneous compartment of infection. In particular, a recent modeling study assumed the liver as the largest solid organ targeted by EBOV infection and predicted that nearly all cells become refractory to infection within seven days of initial infection without antiviral treatment. We compared our observations of EBOV kinetics in multiple anatomic compartments and hepatocellular injury in a critically ill patient with Ebola virus disease (EVD) with this model's predictions. We also explored the model's predictions, with and without antiviral therapy, by recapitulating the model using published inputs and assumptions. Our findings highlight the challenges of modeling EBOV-host dynamics and therapeutic efficacy and emphasize the need for iterative interdisciplinary efforts to refine mathematical models that might advance understanding of EVD pathogenesis and treatment.

Indexed as

Host-Pathogen InteractionsModels, TheoreticalAntiviral AgentsCritical IllnessEbolavirusHemorrhagic Fever, EbolaHumansKineticsLiverRNA, ViralVirus ReplicationAntiviral AgentsRNA, ViralEbola viruslivermathematical modelingviral kinetics

Identifiers

PMID31963118
PMCPMC7019702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.